What is CRMD's current stock price?

CRMD (CorMedix Inc.) is currently trading at $7.98 with a market cap of $626.0M.

What sector is CorMedix Inc. in?

CorMedix Inc. (CRMD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CRMD a good stock to buy?

Analysts have a Buy consensus on CRMD with a price target of $14.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CRMD CorMedix Inc.

Healthcare

$7.98-0.99%ClosedMarket Cap: $626.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

3.51

PEG

0.00

P/B

1.45

P/S

1.56

EV/EBITDA

2.69

DCF Value

$2.47

FCF Yield

31.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

85.8%

Operating Margin

48.4%

Net Margin

45.2%

ROE

50.4%

ROA

22.2%

ROIC

27.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$127.4M	$38.6M	$—
Q4 null	$128.6M	$14.0M	$—
FY null	$311.7M	$163.1M	$—
Q3 null	$104.3M	$108.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$14.00

Target (Median)

$13.50

Target Range

$13.00 - $16.00

3 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Leerink PartnersOutperform

2026-04-28

CitizensMarket Outperform

2026-04-28

RBC CapitalOutperform

2026-04-28

NeedhamBuy

2026-04-27

D. Boral CapitalBuy

2026-04-27

Trading Activity

Insider Trades

View All

Zelnick Kaufman Bethofficer: Chief Legal Officer

SellFri Feb 06

Todisco Josephdirector, officer: Chief Executive Officer

SellFri Feb 06

Hurlburt Elizabethofficer: Chief Operating Officer

SellFri Feb 06

Zelnick Kaufman Bethofficer: Chief Legal Officer

SellTue Jan 27

Zelnick Kaufman Bethofficer: Chief Legal Officer

SellTue Jan 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.46

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Peers